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Medicine, The University of Tokyo, 7-3-1 Hongo, BunkNitric oxide (NO) has been implicated in pancreatic b-cell death in the development of diabetes. The
mechanisms underlying NO-induced b-cell death have not been clearly deﬁned. Recently, receptor-
interacting protein-1 (RIP1)-dependent necrosis, which is inhibited by necrostatin-1, an inhibitor of
RIP1, has emerged as a form of regulated necrosis. Here, we show that NO donor-induced b-cell
death was inhibited by necrostatin-1. Unexpectedly, however, RIP1 knockdown neither inhibited
cell death nor altered the protective effects of necrostatin-1 in NO donor-treated b-cells. These
results indicate that NO donor induces necrostatin-1-inhibitable necrotic b-cell death independent
of RIP1. Our ﬁndings raise the possibility that NO-mediated b-cell necrosis may be a novel form of
signal-regulated necrosis, which play a role in the progression of diabetes.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Insulin insufﬁciency resulting from pancreatic b-cell failure is a
major causative factor in both type 1 and type 2 diabetes [1]. The
spectrum of b-cell failure responsible for these life-threatening dis-
eases ranges from functional impairment and growth arrest to
frank death of b-cells. The demise of b-cells not only contributes
to insufﬁcient b-cell mass in the pancreas, but also triggers inﬁltra-
tion and activation of macrophages in the islets by releasing high
mobility group box 1 (HMGB1) and cyclophilin A, which, in turn,
enhances inﬂammation and accelerates attack by immune cells.chemical Societies. Published by E
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yo, Tokyo 113-8655, Japan.Nitric oxide (NO) and inducible NO synthase (iNOS) have been
implicated in the demise of b-cells in type 1 and type 2 diabetes
[2,3]. NOand iNOS can induce both apoptosis andnecrosis in various
cell types, including pancreatic b-cells. Some studies have shown
that NO mediates both apoptosis and necrosis of b-cells induced
by proinﬂammatory cytokines [4]. Yet other works have demon-
strated that NO preferentially induces necrosis rather than apopto-
sis in cultured b-cells and islet cells [2,5]. Regardless, our
knowledge remains limited about the molecular mechanisms by
which NO induces b-cell death.
Previously, necrosis was thought to be an accidental, uncon-
trolled form of cell death [6], in contrast to apoptosis which is
deﬁned as the genetically programmed cell death. Recently, accu-
mulating evidence clearly indicates that there exists necrotic cell
death which is ﬁnely regulated by a set of signal transduction
pathways and designated as regulated necrosis [7,8]. Speciﬁcally,
death domain receptors (e.g., Fas/CD95, tumor necrosis factor-a
[TNF-a] receptor) have been shown to elicit a form of regu-
lated-necrosis, termed necroptosis, particularly in the presence
of pan-caspase inhibitor, zVAD-fmk. Receptor-interacting pro-
tein-1 (RIP1, also known as RIPK1), an immediate downstream
signaling molecule of the death domain receptors, is a serine/thre-
onine protein kinase. The inhibition of RIP1 by a pharmacologicallsevier B.V. All rights reserved.
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can block necroptosis induced by anti-Fas antibody-plus-zVAD-
fmk or TNF-a-plus-zVAD-fmk. Nec-1 was originally identiﬁed as
a small compound inhibitor of necroptotic cell death induced by
TNF-a-plus-zVAD-fmk in human Jurkat and U937 leukemia cells
[9]. Later it was discovered to be a speciﬁc allosteric inhibitor of
RIP1 kinase [10]. The prevention of necrotic cell death by Nec-1
has been attributed, therefore, to RIP1 inhibition.
Recent studies have shown that Nec-1 can inhibit cell death in
many pathological conditions, such as ischemia/reperfusion injury
and excitotoxicity, as well as in various cell types, including neuro-
nal cells and cardiomyocytes [9,11–21]. Based on these ﬁndings,
Nec-1-inhibitable necroptosis has emerged as a contributor to a
wide range of pathological cell death paradigms. Several of these
studies, however, did not examine the effects of RIP1 knock-
down/knockout in Nec-1-inhibitable cell death [11–16,18–21],
and this represents a gap in knowledge about RIP1 in the necrop-
totic cell death paradigm. A previous study has shown that both
Nec-1 and its analogue, Nec-1i, which is incapable of inhibiting
RIP1 [9], reduce infarct size to a similar extent after ischemia/
reperfusion in isolated mouse hearts [15]. Other studies have
shown that anti-necroptotic effect was speciﬁc for Nec-1, whereas
Nec-1i was ineffective in the prevention of cell death [12]. Taken
together, these ﬁndings raise the possibility that under certain
circumstances Nec-1 and Nec-1i may elicit RIP1-unrelated pro-
survival actions, although RIP1-dependent anti-necroptotic effects
are Nec-1-speciﬁc. This possibility has not yet been investigated.
Hence, it remains an open question whether RIP1 is required for
all types of Nec-1-inhibitable necroptotic cell death. Moreover, it
is not known whether signal-regulated necrotic cellular demise is
involved in pancreatic b-cell death. Here, we show that both
Nec-1 and Nec-1i inhibit NO donor-induced necrotic b-cell death
independent of RIP1.
2. Materials and methods
2.1. Materials
Necrostatin-1 (Nec-1, Enzo Life Sciences, Plymouth Meeting,
PA), Nec-1i, cycloheximide, Akt inhibitor (1L6-Hydroxymethyl-
chiro-inositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbon-
ate) (EMD Biosciences, San Diego, CA), S-nitroso-L-glutathione
(GSNO), S-nitroso-N-acetyl-D,L-penicillamine (SNAP), Dea NONO-
ate, staurosporine (Cayman Chemical, Ann Arbor, MI), reduced glu-
tathione, oxidized glutathione, zVAD-fmk, Hoechst 33342, trypan
blue, Histopaque 1077 (Sigma, St. Louis, MO), mouse tumor necro-
sis factor-a (TNF-a, R&D systems, Minneapolis, MN), SYTOX
Green (Invitrogen, Carlsbad, CA), siRNA oligonucleotides for mouse
RIP1 (M-040150, Thermoscientiﬁc, Waltham, MA), and anti-
HMGB1 (Novus Biologicals, Littleton, CO), anti-cyclophilin A,
anti-Akt, anti-phosphorylated Akt (serine 473) (Cell Signaling
Technology, Danvers, MA), anti-Fas/CD95 (Beckman Coulter, Brea,
CA), anti-RIP1 (BD Transduction Laboratories, Lexington, KY),
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Trevi-
gen, Gaithersburg, MD) antibodies were purchased commercially.
2.2. Cell culture
Rat INS-1/832 insulinoma cells, a kind gift of Dr. C. Newgard [22],
were grown in RPMI 1640 supplemented with 10% FBS, 10 mM
HEPES, 0.05 mM 2-mercaptoethanol, 1 mM sodium pyruvate,
100 U/ml penicillin, and 100 lg/ml streptomycin. Mouse bTC-6
cells (ATCC, Manassas, VA) were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium with 15% FBS, 100 U/ml penicillin, and 100 lg/ml
streptomycin. bTC-6 cells were transfected with siRNA for RIP1 or
control siRNA [23] using Lipofectamine RNAi MAX (Invitrogen).RIP1-deﬁcient and control human Jurkat T-cell lymphoma cells, a
kind gift of Dr. B. Seed [24], were grown in RPMI 1640 supple-
mented with 10% FBS, 10 mM HEPES, 100 U/ml penicillin, and
100 lg/ml streptomycin.
2.3. Mouse islet isolation
The study protocol was approved by the Institutional Animal
Care Committee of Massachusetts General Hospital. The animal care
facility is accredited by the Association for Assessment and Accred-
itation of Laboratory Animal Care. Islets were isolated from male
C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) by collagenase
digestion followed by centrifugation over a Histopaque gradient, and
cultured in RPMI1640 supplemented with 10% FBS, 100 U/ml peni-
cillin, and 100 lg/ml streptomycin, as previously described [25].
2.4. Treatment of cells and islets
Cells and mouse islets were treated with Nec-1 (10–100 lM) or
Nec-1i (100 lM) in the presence or absence of GSNO (100–600 lM),
SNAP (800 lM), anti-Fas/CD95 antibody (200 ng/ml), zVAD-fmk
(30 lM), cycloheximide (3 lg/ml), staurosporine (10 lM) for 24 h
unless otherwise indicated.
2.5. Evaluation of cell viability
Cell viability of INS-1/832, bTC-6, and Jurkat cells was assessed
using Sytox green and Hoechst 33342 according to the manufactur-
ers’ instructions or by the Trypan blue exclusion test. The viability of
islet cells was assessed using Sytox green and ﬂuorescence intensi-
ties were quantiﬁed by NIH Image J 1.410 (National Institutes of
Health, Bethesda, MD). DNA fragmentation was determined by ELI-
SA (Roche Diagnostics, Indianapolis, IN). The metabolic activities of
Jurkat cells were measured by TOX-8 (Sigma).
2.6. Immunoblot analysis
Immunoblotting was performed to evaluate the efﬁciency of
RIP1 knockdown and release of HMGB1 and cyclophilin A to the
culture media, and the effects of GSNO, Nec-1, and Nec-1i on phos-
phorylation of Akt, as previously described [26]. Bands of interest
were scanned using HP Scanjet 4850 (Hewlett-Packard, Palo Alto,
CA) and were quantiﬁed by NIH Image J 1.410.
2.7. Measurement of cellular ATP
Cellular ATP content was determined using commercial kits
from Promega (Madison, WI) and Bioassay Systems (Hayward,
CA). Our pilot experiments showed that the most profound reduc-
tions in cellular ATP levels were observed at 2 h after the addition
of GSNO in INS-1/832 and bTC-6 cells.
2.8. Statistical analysis
The data were compared using One-way ANOVA followed by
Tukey’ s least signiﬁcant difference test. A value of P < 0.05 was
considered statistically signiﬁcant. All data are expressed as
mean ± S.E.M.3. Results
3.1. Nec-1 inhibited NO donor-induced pancreatic b-cell death
Treatment with NO donor, GSNO and SNAP, resulted in cell
death in INS-1/832 and bTC-6 b-cell lines and mouse cultured
Fig. 1. Effects of NO donors and Nec-1 on cell viability of pancreatic b-cells. (A) Treatment with GSNO (200 lM) for 24 h, but not equivalent amounts of reduced (GSH) or
oxidized (GSSG) glutathione, increased dead cells in bTC-6 cells. (B–E) Nec-1 signiﬁcantly decreased GSNO- or SNAP-induced cell death in bTC-6 (GSNO 150 lM [B]; GSNO 100
or 200 lM [C]), INS-1/832 (SNAP 800 lM [D]) and mouse islet cells (GSNO 300 lM [E]). Cell death was assessed by Sytox (A, C, D, E) or trypan blue staining (B). ⁄P < 0.01,
⁄⁄P < 0.001 ⁄⁄⁄P < 0.0001 vs without NO donor, #P < 0.001, ##P < 0.0001 vs NO donor without Nec-1, §P < 0.001 vs GSNO+Nec-1 30 lM, P < 0.0001 vs GSNO 200 lM without
Nec-1.
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trast to GSNO-induced cell death, neither reduced (GSH) nor oxi-
dized (GSSG) glutathione affected cell viability in b-cells. These
ﬁndings indicate that the effect of GSNO on b-cell viability is spe-
ciﬁc for NO. zVAD-fmk (100 lM) did not prevent GSNO-induced
death of bTC-6 cells, whereas zVAD-fmk signiﬁcantly inhibited
staurosporine (10 lM)-induced cell death (Supplementary Fig. 1).
These results indicate that activation of caspases does not have
an important role in NO donor-induced b-cell death.
NO donor-induced b-cell death was accompanied by early
release of HMGB1 and cyclophilin A into the culture media
(Fig. 2 and Supplementary Fig. 2), biomarkers of necrosis [27]. In
contrast, NO donor did not signiﬁcantly increase DNA fragmenta-
tion, a hallmark feature of apoptosis, while robust DNA fragmenta-
tion was induced by staurosporine (10 lM) (Supplementary Fig. 3).
More than 95% of INS-1/832 cells did not show nuclear fragmenta-
tion after 24-h incubation with and without GSNO (500 lM),
whereas staurosporine-induced b-cell death was associated with
nuclear fragmentation (data not shown). These data indicate that
GSNO-induced cellular demise of cultured b-cells is necrotic cell
death rather than apoptosis.
Nec-1 inhibited GSNO-induced cell death in bTC-6 cells in a
dose-dependent manner (Fig. 1B). Nec-1 (100 lM) also signiﬁ-
cantly prevented GSNO- or SNAP-induced cell death in INS-1/832
cells and mouse cultured islets. Consistently, Nec-1 (100 lM) sig-
niﬁcantly increased the number of alive cells after 24-h treatment
with GSNO (150 lM) in bTC-6 cells (Alive cells [105/well]: con-
trol: 9.2 ± 0.2 [mean ± S.zE.M.]; Nec-1 alone: 8.9 ± 0.3; GSNO alone:
2.8 ± 0.04; GSNO+Nec-1: 4.9 ± 0.2, P < 0.001 GSNO alone vs GSNO+-
nec-1). In contrast, Nec-1 (100 lM) did not inhibit staurosporine-
induced death in bTC-6 cells (Supplementary Fig. 1).
Nec-1 blocked GSNO-induced release of HMGB1 and cyclophi-
lin A from cultured b-cells (Fig. 2). However, Nec-1 did not affect
the reductions in intracellular ATP content in GSNO-treated
b-cells (Fig. 2C and data not shown). In contrast to the protective
effects of Nec-1 against GSNO-induced b-cell death, Nec-1(100 lM) failed to inhibit cell death after 24-h deprivation of ser-
um and glucose in bTC-6 cells (Sytox-positive cells [%]: control:
2.5 ± 0.3; control+Nec-1: 2.7 ± 0.3; deprivation: 9.3 ± 0.8; depriva-
tion+Nec-1: 10.4 ± 0.3).
3.2. Neither NO donor-induced cell death nor the protective effect of
Nec-1 was blocked by RIP1 knockdown
Next, we examined the effects of Nec-1i, which is an analogue of
Nec-1 but incapable of inhibiting RIP1. Nec1i has been used as a
negative control for Nec-1 [10]. Unexpectedly, Nec-1i signiﬁcantly
inhibited GSNO-induced cell death in INS-1/832 and bTC-6 cells
(Fig. 3A). These results prompted us to study the effect of RIP1
knockdown. siRNA-mediated knockdown of RIP1 failed to decrease
GSNO-induced b-cell death as comparedwith control siRNA (Fig. 3B
and C and Supplementary Fig. 4). Moreover, Nec-1 effectively pro-
tected b-cells from GSNO-induced cell death even when RIP1 was
knocked down. These results indicate that Nec-1 does not require
RIP1 to protect b-cells from GSNO-induced death.
Treatment with TNF-a (100 ng/ml) or Fas ligand (100 ng/ml) in
combination with zVAD (10, 30, and 100 lM) for up to 24 h did not
signiﬁcantly increase Nec-1-inhibitable cell death in INS-1 and
bTC-6 cells, regardless of the presence or absence of various
concentrations of cycloheximide (0.1–100 lg/ml), a facilitator of
necroptosis in other cell types (Trypan blue-positive cells [%] in
bTC-6 cells: control: 1.3 ± 0.4; Fas ligand [100 ng/ml] + zVAD
[100 lM] + cycloheximide [100 lg/ml]: 3.0 ± 0.6; Fas ligand
[100 ng/ml] + zVAD [100 lM] + cycloheximide [100 lg/ml] + Nec-
1 [100 lM]: 2.7 ± 0.5, P > 0.10, and data not shown).
3.3. The protective effects of Nec-1 and Nec-1i were associated with
(phosphorylation) restoration of suppressed Akt activity in NO donor-
treated b-cells
Previous studies by others and us have shown that treatment
with NO donor results in suppression of Akt activity [28,29], a
Fig. 2. Effects of Nec-1 on NO donor-induced release of HMGB1 and cyclophilin A, and reduced ATP levels in b-cells. (A, B) Nec-1 (100 lM) inhibited GSNO-induced release of
HMGB1 and cyclophilin A in bTC-6 cells (GSNO 150 lM) and INS-1/832 cells (GSNO 500 lM). ⁄P < 0.05, ⁄⁄P < 0.0001 vs without GSNO, #P < 0.0001 vs GSNO without Nec-1. (C)
In contrast, Nec-1 (100 lM) did not alter cellular ATP levels at 2 h after the addition of GSNO (500 lM) in INS-1/832 cells. ⁄⁄P < 0.0001 vs without GSNO.
A B
C D
Fig. 3. RIP1-unrelated protective effects of Nec-1 against NO donor-induced b-cell death. (A) GSNO-induced cell death was signiﬁcantly prevented by Nec-1 (N), a potent
inhibitor of RIP1, and its analogue, Nec-1i (I), which is incapable of inhibiting RIP1, in bTC-6 and INS-1/832 cells. ⁄P < 0.01, ⁄⁄P < 0.0001 vs without GSNO, #P < 0.001 vs GSNO
(100 or 300 lM) without Nec-1, §P < 0.001 vs GSNO (200 or 500 lM) without Nec-1, P < 0.01 vs GSNO 300 lM + Nec-1, –P < 0.001 vs GSNO (200 or 500 lM) + Nec-1. (B)
siRNA-mediated knockdown of RIP1 (siRIP1) did not block GSNO (100 lM)-induced cell death in bTC-6 cells, as compared with control siRNA. Moreover, Nec-1 (100 lM)
effectively inhibited GSNO (100 lM)-induced cell death in bTC-6 cells transfected with siRNA for RIP1 as well as control siRNA. ⁄P < 0.05, ⁄⁄P < 0.0001 vs without GSNO,
#P < 0.05 vs GSNO + control siRNA without Nec-1, §P < 0.0001 vs GSNO without Nec-1. (C, D) Nec-1 and Nec-1i almost completely reversed decreased Akt phosphorylation in
GSNO-treated INS-1/832 cells. IB: immunoblotting.
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remain elusive. We, therefore, examined the effects of Nec-1 and
Nec-1i on Akt activity (phosphorylation) in NO donor-treated b-
cells. As shown previously [28,29], treatment with GSNO for 5 h de-
creased phosphorylation of Akt in INS-1/832 cells. Both Nec-1 andNec-1i almost completely reversed the decreased phosphorylation
of Akt in GSNO-treated b-cells (Fig. 3C and D). In contrast, neither
Nec-1 nor Nec-1i altered phosphorylation of Akt in the absence of
NO donor. Akt and GAPDH protein expression were not altered by
GSNO, Nec-1, or Nec-1i. On the other hand, Akt inhibitor
Fig. 4. Effects of NO donor and Nec-1 in wild-type and RIP1-deﬁcient Jurkat cells. (A) GSNO induced cell death in control wild-type (RIP1-proﬁcient) Jurkat cells in a dose-
dependent manner. Both Nec-1 (N) (100 lM) and Nec-1i (I) (100 lM) inhibited GSNO-induced cell death in wild-type Jurkat cells. ⁄⁄P < 0.0001 vs without GSNO, ##P < 0.0001
vs GSNO 400 lM without Nec-1, §§P < 0.0001 vs GSNO 600 lM without Nec-1. (B) GSNO (600 lM) induced cell death in both wild-type (RIP1+ or WT) and RIP1-deﬁcient
(RIP1-) Jurkat cells. Nec-1 (100 lM) signiﬁcantly decreased GSNO-induced cell death in both wild-type and RIP1-deﬁcient Jurkat cells. Immunoblotting conﬁrmed that RIP1
was expressed in wild-type, but not RIP1-deﬁcient, Jurkat cells. ⁄P < 0.001, ⁄⁄P < 0.0001 vs without GSNO, #P < 0.001 vs WT with GSNO alone, §P < 0.0001 vs GSNO alone. Cell
death was assessed by Trypan blue staining. IB: immunoblotting.
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in INS-1/832 cells (Trypan blue-positive cells [%]: control:
1.7 ± 0.4; Akt inhibitor: 69.9 ± 10.7; Akt inhibitor + Nec-1:
71.8 ± 14.5).
3.4. Both Nec-1 and Nec-1i inhibited GSNO-induced cell death in Jurkat
cells
To further investigate the role of RIP1 in NO donor-induced cell
death, we examined the effects of Nec-1 and Nec-1i in Jurkat cells,
in which RIP1-dependent death domain receptors (e.g., Fas/CD95)-
mediated necroptosis has been established [10]. Both Nec-1 and
Nec-1i signiﬁcantly inhibited GSNO-induced cell death (Fig. 4A).
Consistently, GSNO caused cell death in both control wild-type
(RIP1-proﬁcient) and RIP1-deﬁcient Jurkat cells (Fig. 4B and Supple-
mentary Fig. 5), whereas RIP1 deﬁciency prevented anti-Fas anti-
body-plus-zVAD-fmk induced cell death (Trypan blue-positive
cells [%]: WT without treatment: 1.7 ± 0.3; WT with Fas + zVAD:
10.2 ± 0.9; RIP1/ with Fas + zVAD: 3.2 ± 0.2, P < 0.001 WT with
Fas + zVAD vs. RIP1/ with Fas + zVAD) as shown previously
[10]. RIP1-deﬁcient Jurkat cells were slightly, but signiﬁcantly less
sensitive to GSNO-induced cell death as compared with wild-type
Jurkat cells. Nonetheless, Nec-1 effectively inhibited GSNO-
induced cell death in both wild-type and RIP1-deﬁcient Jurkat cells.
4. Discussion
Here, we demonstrate that Nec-1 signiﬁcantly inhibits NO
donor-induced necrotic death of pancreatic b-cells. Of interest,
knockdown of RIP1 had little, if any, effect on NO donor-induced
cell death in b-cells (Fig. 3B), although Nec-1 is a potent inhibitor
of RIP1 [10]. Moreover, RIP1 knockdown did not block the protec-
tive effects of Nec-1 against NO donor-induced cell death in b-cells.
In line with this, Nec-1i also exhibited protective effects against NO
donor-induced cell death. Of note, the pro-survival effect of Nec-1i
is consistent with a previous study which showed that both Nec-1
and Nec-1i protect isolated heart from ischemia/reperfusion injury
[30]. Together, these results clearly indicate that Nec-1 and Nec-1i
inhibit NO donor-induced necrotic cell death independent of the
inhibition of RIP1 in b-cells.
Our data also indicate that RIP1 does not play a major role in NO
donor-induced death of Jurkat cells. To the best of our knowledge,
no study has shown that death domain receptors (e.g., Fas/CD95,
TNF-a receptor) have an important role in NO donor-induced celldeath in any cell type. Our ﬁndings support the argument that
NO-mediated necrotic death of b-cells and Jurkat cells may be
regulated by (an) as yet unidentiﬁed molecular mechanism(s),
whereby RIP1-unrelated target(s) of Nec-1 and Nec-1i are
involved.
The recently revised proposal of the Nomenclature Committee
on Cell Death encourages not to use the term ‘‘necroptosis’’ as a
synonym of regulated necrosis, but to limit its use to indicate
RIP1- and/or RIP3-dependent regulated necrosis [8]. Based on this
recommendation, NO donor-induced cell death is not classiﬁed as
necroptosis although it is inhibited by Nec-1. It is important to
note, however, that our data support the argument that there
may exist a novel type of Nec-1-inhibitable, but RIP-1-independent
regulated necrosis.
We found that Nec-1 and Nec-1i signiﬁcantly inhibited NO
donor-induced suppression of Akt activity in b-cells (Fig. 3C and
D). Of note, Nec-1 failed to inhibit Akt inhibitor-induced b-cell
death. Previous studies have shown that Akt inhibits ceramide-in-
duced non-apoptotic programmed cell death with a necrosis-like
morphology in glioma cells [31] and cytokine-induced necrosis as
well as apoptosis of cultured b-cells [32]. Taken together, these
ﬁndings suggest that suppression of Akt activity and its mitigation
may play a role in NO donor-induced necrosis and its prevention
by Nec-1 in b-cells.
Apparently contradictory results have been also reported con-
cerning the role of RIP1 in NO donor-induced necrotic cell death.
Contrary to our ﬁndings, a previous study showed that NO donor,
Dea NONOate (10 lM)-induced necrotic death of cultured rat pul-
monary microvascular endothelial cells is completely blocked by
knockdown of RIP1 as well as by Nec-1 [33]. This discrepancy
might be explained by differences in cell types and NO donors.
Treatment with Dea NONOate (10 lM) for 24 h did not increase
cell death in INS-1, bTC-6, or Jurkat cells. Less than 3% of the INS-
1, bTC-6, and Jurkat cells were dead following 24-h incubation with
or without 10 lM of Dea NONOate, whereas approximately 90% of
rat pulmonary microvascular endothelial cells undergo necrosis
after 14-h treatment with Dea NONOate (10 lM) in that study
[33]. Consequently, it is possible that the role of RIP1 in NO-med-
iated necrotic cell death may vary depending on the cell types, the
quantitative and qualitative differences between NO donors, and
the cellular context.
RIP1-deﬁcient Jurkat cells were slightly, but signiﬁcantly less
sensitive to GSNO-induced cell death (Fig. 4B). Although we do
not have clear explanation, it is possible that signaling pathways
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might be altered by RIP1 deﬁciency. Our data, however, do not
exclude an alternative possibility that RIP1 could play a role in
NO donor-induced death of Jurkat cells. Regardless, our results
clearly indicate that RIP1 is not necessary for the protective effects
of Nec-1 in Jurkat cells.
Earlier studies have proposed that ATP depletion, which results
from NO-mediated inhibition of ATP production, plays an impor-
tant role in NO-induced necrosis [34,35]. Consistent with previous
studies [29,30], we found that treatment with NO donor decreased
intracellular ATP content in b-cells. Importantly, however, the inhi-
bition of necrotic cell death by Nec-1 was not associated with
reversal of GSNO-induced reductions in intracellular ATP levels
(Fig. 2C). These ﬁndings raise the possibility that NO can cause
necrotic cell death via signaling pathways that are unrelated to
ATP reduction. Nonetheless, it is important to note that our results
do not exclude the possibility that under certain conditions NO can
cause necrosis by ATP depletion, as well.
Necrosis is associated with early release of HMGB1 and cyclo-
philin A, which has been used as a biomarker of necrotic cell death
[2]. HMGB1 is a ligand of receptor for advanced glycation endprod-
ucts (RAGE) and Toll-like receptors, and therefore acts as a potent
inducer of inﬂammation [36]. Previous studies have shown that
extracellular HMGB1 enhances autoimmune insulitis and progres-
sion of diabetes in non-obese diabetic mice [37] and promotes
early graft failure during islet transplantation in mice [38]. In addi-
tion, secreted cyclophilin A functions as a proinﬂammatory cyto-
kine and potent chemoattractant of immune cells, including
macrophages and T-cells [39]. Release of HMGB1 and cyclophilin
A from NO donor-treated b-cells was prevented by Nec-1. Taken
together, one can reasonably speculate that NO-mediated necrotic
b-cell death might trigger or enhance inﬁltration of macrophages
and T-cells into the islets, which in turn leads to the aggravated
inﬂammation, immune attack, and resultant b-cell dysfunction in
diabetes. In aggregate, our ﬁndings suggest that signal-regulated
necrotic cell death may play a role in the NO-involved pathogene-
sis of b-cell failure in diabetes.
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